Biotechnology Daily
more-
Orion to use Aitia’s ‘digital twins’ to identity potential new cancer drugs
Finnish biotech Orion has spied potential in Aitia’s “digital twin” tech to develop new cancer…
Market Watch
more-
Weekly Market Review – January 11, 2025
Stock Markets Major U.S. indexes are down for the shortened trading week due to market…
Bio Business News
more
OncoC4 founders take own science under their wing in new biotech merger
OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its…
BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials
BioAge Labs is eyeing around $180 million in initial proceeds…
Amgen reports first phase 3 win for $400M eczema drug, but Dupixent rivalry doubts remain
Amgen has shared (PDF) the first phase 3 data on…
World News
more
Stocks close with a round of records, Dow clinches 35,000
U.S. stocks swept to another round of records Monday as…
Equifax stock surges toward biggest gain in 12 years after ‘impressive’ business update
Shares of Equifax Inc. EFX, +7.84% shot up 9.3% into…
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Weekly Market Review – January 11, 2025
Weekly Market Review – January 11, 2025
Weekly Market Review – January 4, 2025
Orion to use Aitia’s ‘digital twins’ to identity potential new cancer drugs
Windtree’s cardiogenic shock med raises blood pressure in latest phase 2 win
Merck’s Keytruda-LAG-3 combo fails to tame tough colorectal cancer in phase 3
New PicnicHealth service brings observational clinical trial research to the virtual world
OncoC4 founders take own science under their wing in new biotech merger
BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials
Amgen reports first phase 3 win for $400M eczema drug, but Dupixent rivalry doubts remain